Drugs / SL-T10
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06344715 | Oct 2022 → Oct 2024 | castration-resistant prostate carcinoma | SL VAXiGEN | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SL-T10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06344715 ↗ |
| Modality | Vaccine | “A therapeutic DNA vaccine containing three prostate cancer-specific antigen genes and genetic adjuvants” NCT06344715 ↗ |
| Route | Intramuscular | “SL-T10 (3mg, multiple injections, IM)” NCT06344715 ↗ |